Evidence map›Paper›PMID 29632420›Full record

ReviewWorld journal of gastroenterology2018

Thrombocytopenia after liver transplantation: Should we care?

Kazuhiro Takahashi, Shunji Nagai, Mohamed Safwan, Chen Liang, Nobuhiro Ohkohchi

Open access · hybridAbstract readReview
In one paragraph

Review in World journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. bioRxiv : the preprint server for biology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Cytopenias in Autoimmune Liver Diseases-A Review.Journal of clinical medicine · 2025
    Review
  9. Living with a transplanted liver is associated with cytopenias: a nationwide cohort study.Frontiers in gastroenterology (Lausanne, Switzerland) · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Effects ofBiomedicines · 2023
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Kazuhiro TakahashiDepartment of Surgery, Division of Gastroenterological and Hepatobiliary Surgery, and Organ Transplantation, University of Tsukuba, Tsukuba, Ibaraki 3058575, Japan.
Shunji NagaiTransplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, ML 48202, United States.
Mohamed SafwanTransplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, ML 48202, United States.
Chen LiangDepartment of Surgery, Division of Gastroenterological and Hepatobiliary Surgery, and Organ Transplantation, University of Tsukuba, Tsukuba, Ibaraki 3058575, Japan.
Nobuhiro OhkohchiDepartment of Surgery, Division of Gastroenterological and Hepatobiliary Surgery, and Organ Transplantation, University of Tsukuba, Tsukuba, Ibaraki 3058575, Japan. nokochi3@md.tsukuba.ac.jp.
University of Tsukuba · JPHenry Ford Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transient thrombocytopenia is a common phenomenon after liver transplantation. After liver transplantation (LT), platelet count decreases and reaches a nadir on postoperative days 3-5, with an average reduction in platelet counts of 60%; platelet count recovers to preoperative levels approximately two weeks after LT. The putative mechanisms include haemodilution, decreased platelet production, increased sequestration, medications, infections, thrombosis, or combination of these processes. However, the precise mechanisms remain unclear. The role of platelets in liver transplantation has been highlighted in recent years, and particular attention has been given to their effects beyond hemostasis and thrombosis. Previous studies have demonstrated that perioperative thrombocytopenia causes poor graft regeneration, increases the incidence of postoperative morbidity, and deteriorates the graft and decreases patient survival in both the short and long term after liver transplantation. Platelet therapies to increase perioperative platelet counts, such as thrombopoietin, thrombopoietin receptor agonist, platelet transfusion, splenectomy, and intravenous immunoglobulin treatment might have a potential for improving graft survival, however clinical trials are lacking. Further studies are warranted to detect direct evidence on whether thrombocytopenia is the cause or result of poor-graft function and postoperative complications, and to determine who needs platelet therapies in order to prevent postoperative complications and thus improve post-transplant outcomes.

Indexed as

AllograftsEnd Stage Liver DiseaseGraft RejectionGraft SurvivalHumansImmunoglobulins, IntravenousLiverLiver RegenerationLiver TransplantationPerioperative PeriodPlatelet TransfusionPostoperative ComplicationsReceptors, ThrombopoietinSplenectomyThrombocytopeniaThrombopoietinImmunoglobulins, IntravenousReceptors, ThrombopoietinThrombopoietinIntravenous immunoglobulin treatmentLiver regenerationLiver transplantationPlateletPlatelet therapyThrombocytopeniaThrombopoietin receptor agonist

Identifiers

PMID29632420
PMCPMC5889819
OpenAlexW2795413207

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.